Notably, mutated EGFR in lung cancer and KRAS in colorectal cancer are therapeutic targets of FDA‐approved drugs, and their lower carrier rates in early‐onset cancers may restrict relevant drug applications. This evidence concerns the gene EGFR and lung carcinoma.